SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasia

BCR-ABL1-targeting tyrosine kinase inhibitors (TKIs) have revolutionized treatment of Philadelphia chromosome-positive (Ph(+)) hematologic neoplasms. Nevertheless, acquired TKI resistance remains a major problem in chronic myeloid leukemia (CML), and TKIs are less effective against Ph(+) B-cell acut...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leukemia
Egile Nagusiak: Gu, Shengqing, Sayad, Azin, Chan, Gordon, Yang, Wentian, Lu, Zhibin, Virtanen, Carl, Van Etten, Richard A., Neel, Benjamin G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6005183/
https://ncbi.nlm.nih.gov/pubmed/28804122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.250
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak